GT Biopharma, Inc. (GTBP)

GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $2.23 million. The enterprise value is -$2.99 million.

Market Cap	2.23M
Enterprise Value	-2.99M

Important Dates

The next estimated earnings date is Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

GT Biopharma has 3.56 million shares outstanding. The number of shares has increased by 64.62% in one year.

Current Share Class	3.56M
Shares Outstanding	3.56M
Shares Change (YoY)	+64.62%
Shares Change (QoQ)	+18.19%
Owned by Insiders (%)	10.99%
Owned by Institutions (%)	9.57%
Float	2.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.68
P/TBV Ratio	0.78
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.09

Current Ratio	3.09
Quick Ratio	2.27
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -181.99% and return on invested capital (ROIC) is -130.90%.

Return on Equity (ROE)	-181.99%
Return on Assets (ROA)	-82.45%
Return on Invested Capital (ROIC)	-130.90%
Return on Capital Employed (ROCE)	-224.46%
Revenue Per Employee	n/a
Profits Per Employee	-$9.48M
Employee Count	1
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.14% in the last 52 weeks. The beta is 1.32, so GT Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.32
52-Week Price Change	-81.14%
50-Day Moving Average	0.80
200-Day Moving Average	1.95
Relative Strength Index (RSI)	42.00
Average Volume (20 Days)	4,495,638

Short Selling Information

The latest short interest is 1.04 million, so 29.37% of the outstanding shares have been sold short.

Short Interest	1.04M
Short Previous Month	244,248
Short % of Shares Out	29.37%
Short % of Float	47.84%
Short Ratio (days to cover)	0.27

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-10.81M
Pretax Income	-9.40M
Net Income	-9.48M
EBITDA	n/a
EBIT	-10.81M
Earnings Per Share (EPS)	-$3.94

Balance Sheet

The company has $5.23 million in cash and n/a in debt, giving a net cash position of $5.23 million or $1.47 per share.

Cash & Cash Equivalents	5.23M
Total Debt	n/a
Net Cash	5.23M
Net Cash Per Share	$1.47
Equity (Book Value)	4.82M
Book Value Per Share	0.87
Working Capital	4.82M

Cash Flow

Operating Cash Flow	-10.42M
Capital Expenditures	n/a
Free Cash Flow	-10.42M
FCF Per Share	-$2.93

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-64.62%
Shareholder Yield	-64.62%
Earnings Yield	-424.40%
FCF Yield	-466.52%

Analyst Forecast

The average price target for GT Biopharma is $11.00, which is 1,651.87% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.00
Price Target Difference	1,651.87%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.

Last Split Date	Feb 5, 2024
Split Type	Reverse
Split Ratio	1:30

Scores

Altman Z-Score	n/a
Piotroski F-Score	1